Peptides by condition · Weight, blood sugar, liver and gut

Peptides studied for obesity

Checked against our study pages and the FDA labelsPublished by PepVault

Our library holds 71 study pages on obesity: 63 in people (55 of them meta-analyses or randomized trials), and 8 in animals. They studied 23 compounds, with this many study pages each: Semaglutide 12, Tirzepatide 11, Setmelanotide 8, Retatrutide 7, Liraglutide 3, Cagrilintide 3, Survodutide 3, Orforglipron 2, CagriSema 2, Mazdutide 2, Pramlintide 2, Amycretin 3, Ecnoglutide 1, Efinopegdutide 1, Exenatide 1, Eloralintide 1, Enicepatide 1, Petrelintide 1, VK2735 1, AOD-9604 3, 5-Amino-1MQ 1, MOTS-c 1 and SLU-PP-332 1.

What the research on obesity looks like

Obesity is a long-term disease in which extra body fat raises the risk of diabetes, heart disease, joint pain and more. It is the condition with by far the most peptide research in people: the drugs that copy gut hormones such as GLP-1 have been tested in large trials lasting a year or longer, and several are now prescription medicines.

Obesity trials mostly measure the share of body weight lost against a placebo group, and how many people reach a set amount of loss. Some also scan the body to split the loss into fat and lean mass, or follow blood fats, blood pressure and heart events.

When reading these studies, look at how long the trial ran, whether the comparison was a placebo or another drug, and what happened after people stopped. A result in obese mice is a first step and says little about a person.

Our study pages on obesity by design: Trials in people 55, Other in people 8, Animals 8, Cells 0, of 71.Trials in people55Other in people8Animals8Cells0
How many of the 71 study pages on this condition reach each design, strongest at the top: meta-analyses and randomized trials in people, other studies in people, animals, cells.
A smiling woman in a dark training top in her kitchen, holding a glass of water

Model. Individual results vary.

PepVault for iPhone

Track your own progress in PepVault

Doses, vials, weight and side effects in one log.

Download on the App Store

7 days free on the yearly plan for new subscribers.

The 71 studies, by compound

Grouped by the compound each study is filed under, and within each, strongest design first. Each line gives the design, who was studied, how many and the year, before the finding.

  1. Semaglutide

    12 in people

    For obesity, 12 of our study pages are filed under Semaglutide: 1 meta-analysis and 11 randomized trials in people. The largest in people enrolled 17,604 people and was published in 2024. They were published from 2021 to 2025, in J ASEAN Fed Endocr Soc, Nat Med, N Engl J Med, Lancet Diabetes Endocrinol, Lancet, JAMA, NEJM Evid and Diabetes Obes Metab.

    FDA-approved, with a use tied to obesity on its label: Wegovy (injection) for weight loss and keeping it off, lowering heart risk in adults with heart disease and excess weight, and a fatty-liver disease (MASH) with moderate to advanced scarring; Wegovy (tablet) for weight loss and keeping it off, and lowering heart risk in adults with heart disease and excess weight. Under Ozempic and Rybelsus it is approved for other uses.

  2. Tirzepatide

    11 in people

    For obesity, 11 of our study pages are filed under Tirzepatide: 11 randomized trials in people. The largest in people enrolled 2,539 people and was published in 2022. They were published from 2022 to 2026, in N Engl J Med, Clin Obes, Lancet, JAMA, Diabetes Obes Metab, Nat Med and Sleep Med.

    FDA-approved, with a use tied to obesity on its label: Zepbound (injection) for weight loss and keeping it off, and moderate to severe obstructive sleep apnea in adults with obesity. Under Mounjaro it is approved for other uses.

  3. Setmelanotide

    8 in people

    For obesity, 8 of our study pages are filed under Setmelanotide: 1 meta-analysis, 1 randomized trial and 6 clinical trials in people. The largest in people pooled 185 people and was published in 2026. They were published from 2017 to 2026, in Expert Opin Drug Saf, N Engl J Med, Front Behav Neurosci, Lancet Diabetes Endocrinol, Orphanet J Rare Dis and Mol Metab.

    FDA-approved, with a use tied to obesity on its label: Imcivree (injection) for reducing excess weight and keeping it off in rare kinds of obesity: acquired hypothalamic obesity (age 4 and older), and Bardet-Biedl syndrome or a confirmed POMC, PCSK1 or LEPR gene deficiency (age 2 and older).

  4. Retatrutide

    6 in people · 1 in animals

    For obesity, 7 of our study pages are filed under Retatrutide: 1 meta-analysis, 3 randomized trials and 2 clinical trials in people, and 1 animal study (mice). The largest in people pooled 29,506 people and was published in 2025. They were published from 2023 to 2026, in Obesity (Silver Spring), N Engl J Med, Diabetes Obes Metab, Kidney Int Rep and Int J Obes (Lond).

    Retatrutide has no FDA-approved product: Drugs@FDA lists no application for it, and FDA writes that it is not a component of any FDA-approved drug.

  5. Liraglutide

    3 in people

    For obesity, 3 of our study pages are filed under Liraglutide: 3 randomized trials in people. The largest in people enrolled 3,731 people and was published in 2015. They were published from 2015 to 2022, in N Engl J Med and JAMA.

    FDA-approved, with a use tied to obesity on its label: Saxenda (injection) for weight loss and keeping it off, in adults and in children 12 and older with obesity. Under Victoza it is approved for other uses.

  6. Cagrilintide

    3 in people

    For obesity, 3 of our study pages are filed under Cagrilintide: 3 randomized trials in people. The largest in people enrolled 3,417 people and was published in 2025. They were published from 2021 to 2026, in N Engl J Med, Lancet and Diabetes Obes Metab.

    Cagrilintide has no FDA-approved product: Drugs@FDA lists no application for it, and FDA writes that it is not a component of any FDA-approved drug.

  7. Survodutide

    3 in people

    For obesity, 3 of our study pages are filed under Survodutide: 3 randomized trials in people. The largest in people enrolled 725 people and was published in 2026. They were published from 2024 to 2026, in N Engl J Med, Lancet Diabetes Endocrinol and Nat Med.

    Survodutide has no FDA-approved product: Drugs@FDA lists no application for it. FDA writes that it has warned companies that illegally sold unapproved drugs containing survodutide, among others, labeled “for research purposes”.

  8. Orforglipron

    2 in people

    For obesity, 2 of our study pages are filed under Orforglipron: 2 randomized trials in people. The largest in people enrolled 3,127 people and was published in 2025. They were published from 2025 to 2026, in N Engl J Med and Lancet.

    FDA-approved, with a use tied to obesity on its label: Foundayo (tablet) for weight loss and keeping it off, in adults with obesity or with excess weight and a weight-related condition.

  9. CagriSema

    2 in people

    For obesity, 2 of our study pages are filed under CagriSema: 2 randomized trials in people. The largest in people enrolled 1,206 people and was published in 2025. They were published from 2025 to 2026, in N Engl J Med and Lancet Diabetes Endocrinol.

    CagriSema, cagrilintide combined with semaglutide, has no FDA-approved product: Drugs@FDA lists no application with cagrilintide in it. Semaglutide on its own is approved (Ozempic, Wegovy).

  10. Mazdutide

    2 in people

    For obesity, 2 of our study pages are filed under Mazdutide: 2 randomized trials in people. The largest in people enrolled 610 people and was published in 2025. They were published from 2025 to 2026, in N Engl J Med and JAMA.

    Mazdutide has no FDA-approved product: Drugs@FDA lists no application for it. FDA writes that it has warned companies that illegally sold unapproved drugs containing mazdutide, among others, labeled “for research purposes”.

  11. Pramlintide

    2 in people

    For obesity, 2 of our study pages are filed under Pramlintide: 2 randomized trials in people. The largest in people enrolled 411 people and was published in 2008. They were published from 2007 to 2008, in Diabetes Care and J Clin Endocrinol Metab.

    FDA-approved for other uses, not for obesity: Symlin for adding to mealtime insulin in type 1 or type 2 diabetes when insulin alone has not reached the blood sugar goal.

  12. Amycretin

    2 in people · 1 in animals

    For obesity, 3 of our study pages are filed under Amycretin: 2 randomized trials in people, and 1 animal study (mice and rats). The largest in people enrolled 144 people and was published in 2025. All were published in 2025, in Lancet and EBioMedicine.

    Amycretin has no FDA-approved product: Drugs@FDA lists no application for it.

  13. Ecnoglutide

    1 in people

    For obesity, 1 of our study pages is filed under Ecnoglutide: 1 randomized trial in people. It enrolled 664 people and was published in 2025, in Lancet Diabetes Endocrinol.

    Ecnoglutide has no FDA-approved product: Drugs@FDA lists no application for it.

  14. Efinopegdutide

    1 in people

    For obesity, 1 of our study pages is filed under Efinopegdutide: 1 randomized trial in people. It enrolled 195 people and was published in 2021, in Clin Obes.

    Efinopegdutide has no FDA-approved product: Drugs@FDA lists no application for it.

  15. Exenatide

    1 in people

    For obesity, 1 of our study pages is filed under Exenatide: 1 randomized trial in people. It enrolled 119 people and was published in 2021, in J Clin Endocrinol Metab.

    FDA-approved for other uses, not for obesity: Byetta (injection) for blood sugar control, with diet and exercise, in adults with type 2 diabetes.

  16. Eloralintide

    1 in people

    For obesity, 1 of our study pages is filed under Eloralintide: 1 randomized trial in people. It enrolled 100 people and was published in 2026, in Diabetes Obes Metab.

    Eloralintide has no FDA-approved product: Drugs@FDA lists no application for it.

  17. Enicepatide

    1 in people

    For obesity, 1 of our study pages is filed under Enicepatide: 1 randomized trial in people. It was published in 2026, in Mol Metab, and our page does not give its size.

    Enicepatide has no FDA-approved product: Drugs@FDA lists no application for it.

  18. Petrelintide

    1 in people

    For obesity, 1 of our study pages is filed under Petrelintide: 1 randomized trial in people. It was published in 2026, in Diabetes Obes Metab, and our page does not give its size.

    Petrelintide has no FDA-approved product: Drugs@FDA lists no application for it.

  19. VK2735

    1 in people

    For obesity, 1 of our study pages is filed under VK2735: 1 randomized trial in people. It was published in 2026, in Obesity (Silver Spring), and our page does not give its size.

    VK2735 has no FDA-approved product: Drugs@FDA lists no application for it.

  20. AOD-9604

    3 in animals

    For obesity, 3 of our study pages are filed under AOD-9604: 3 animal studies (mice and obese Zucker rats). None of them is in people. They were published from 1994 to 2001, in Endocrinology, Horm Res and Biochem Mol Biol Int.

    AOD-9604 has no FDA-approved product: Drugs@FDA lists no application for it.

  21. 5-Amino-1MQ

    1 in animals

    For obesity, 1 of our study pages is filed under 5-Amino-1MQ: 1 animal study (mice). It was published in 2022, in Sci Rep.

    5-amino-1MQ has no FDA-approved product: Drugs@FDA lists no application for it.

  22. MOTS-c

    1 in animals

    For obesity, 1 of our study pages is filed under MOTS-c: 1 animal study (mice). It was published in 2015, in Cell Metab.

    MOTS-c has no FDA-approved product: Drugs@FDA lists no application for it.

  23. SLU-PP-332

    1 in animals

    For obesity, 1 of our study pages is filed under SLU-PP-332: 1 animal study (mice). It was published in 2024, in J Pharmacol Exp Ther.

    SLU-PP-332 has no FDA-approved product: Drugs@FDA lists no application for it.

Side by side

For the 23 compounds on this page: studies in people, studies in animals or cells, the size of the largest study in people, and the FDA status from the labels our status pages read (a dash where they hold no record).

CompoundIn peopleAnimals or cellsLargest in peopleFDA
Semaglutide12017,604Approved, a use tied to it
Tirzepatide1102,539Approved, a use tied to it
Setmelanotide80185Approved, a use tied to it
Retatrutide6129,506Not approved
Liraglutide303,731Approved, a use tied to it
Cagrilintide303,417Not approved
Survodutide30725Not approved
Orforglipron203,127Approved, a use tied to it
CagriSema201,206Not approved
Mazdutide20610Not approved
Pramlintide20411Approved for other uses
Amycretin21144Not approved
Ecnoglutide10664Not approved
Efinopegdutide10195Not approved
Exenatide10119Approved for other uses
Eloralintide10100Not approved
Enicepatide10—Not approved
Petrelintide10—Not approved
VK273510—Not approved
AOD-960403—Not approved
5-Amino-1MQ01—Not approved
MOTS-c01—Not approved
SLU-PP-33201—Not approved

What the studies did not show

Each study page names its own limits. These are the questions still open, in the study pages’ words.

This page is a reading of published studies, not medical advice. A diagnosis, and what to do about it, is a conversation with a clinician.

Questions

Which peptides have been studied for obesity?

Our 71 study pages on obesity are filed under 23 compounds, with this many each: Semaglutide 12, Tirzepatide 11, Setmelanotide 8, Retatrutide 7, Liraglutide 3, Cagrilintide 3, Survodutide 3, Orforglipron 2, CagriSema 2, Mazdutide 2, Pramlintide 2, Amycretin 3, Ecnoglutide 1, Efinopegdutide 1, Exenatide 1, Eloralintide 1, Enicepatide 1, Petrelintide 1, VK2735 1, AOD-9604 3, 5-Amino-1MQ 1, MOTS-c 1 and SLU-PP-332 1. Semaglutide has the most.

Have any been tested in people with obesity?

Yes: 63 of the 71 were in people, 55 of them meta-analyses or randomized trials (Semaglutide, Tirzepatide, Setmelanotide, Retatrutide, Liraglutide, Cagrilintide, Survodutide, Orforglipron, CagriSema, Mazdutide, Pramlintide, Amycretin, Ecnoglutide, Efinopegdutide, Exenatide, Eloralintide, Enicepatide, Petrelintide and VK2735). The largest pooled 29,506 people: “Retatrutide: top odds of 15% or more weight loss across 19 trials” (2025).

Is any peptide FDA-approved for obesity?

Yes, with a use tied to obesity on their FDA labels: Semaglutide as Wegovy; Tirzepatide as Zepbound; Setmelanotide as Imcivree; Liraglutide as Saxenda; Orforglipron as Foundayo. 18 other compounds here with an FDA record have no use tied to it.

How large were the studies in people on obesity?

Of the 63 in people, 50 give their size on our pages: 16 had 1,000 people or more, 28 had 100 to 999 and 6 had fewer than 100. The largest, a meta-analysis from 2025, pooled 29,506.

What did the animal and cell studies on obesity use?

8 animal studies (mice, rats and obese Zucker rats), filed under Retatrutide, Amycretin, SLU-PP-332, 5-Amino-1MQ, MOTS-c and AOD-9604. A result in animals or cells shows what to test next, not what happens in a person.

What is the newest study on obesity here?

Of our study pages on obesity, the newest is “Setmelanotide: injection-site reactions in 96% in pooled trials”, a meta-analysis in people published in 2026.

How this page was built

A study page is listed here only where we read its question, design and finding and the study was about this condition: its subjects had the condition, or were an animal or cell model of it, and the study gave them the compound. A study that only mentions the condition is not listed.

Studies are grouped by the compound each is filed under and ordered by design: meta-analyses and randomized trials in people first, then other studies in people, then animals, then cells, and within a group by size and then by year. The FDA status comes from the labels our legal-status and brand pages read.

Track it in the app

PepVault for iPhone

Track your own progress in PepVault

Doses, vials, weight and side effects in one log.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo